Rating Reporting: Is Acorda Therapeutics (ACOR) a Buy? JPMorgan Upgrades It

November 30, 2016 - By olga

Rating Reporting:  Is Acorda Therapeutics (ACOR) a Buy? JPMorgan Upgrades It

Acorda Therapeutics (ACOR) Upgrade

Equity research analysts at JPMorgan’s equities research division increased Acorda Therapeutics (ACOR)‘s stock from a Neutral to Overweight on 30 November.

The stock increased 0.73% or $0.15 during the last trading session, hitting $20.8. About 497,587 shares traded hands. Acorda Therapeutics Inc (ACOR) has declined 28.57% since April 27, 2016 and is downtrending. It has underperformed by 33.80% the S&P500.

Analysts await Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings on February, 9. They expect $-0.13 earnings per share, down 161.90% or $0.34 from last year’s $0.21 per share. After $-0.28 actual earnings per share reported by Acorda Therapeutics Inc for the previous quarter, Wall Street now forecasts -53.57% EPS growth.

Insitutional Activity: The institutional sentiment decreased to 0.89 in Q2 2016. Its down 0.24, from 1.13 in 2016Q1. The ratio dropped, as 32 funds sold all Acorda Therapeutics Inc shares owned while 45 reduced positions. 14 funds bought stakes while 73 increased positions. They now own 43.11 million shares or 7.66% less from 46.68 million shares in 2016Q1.

Gsa Limited Liability Partnership last reported 0.03% of its portfolio in the stock. Pub Employees Retirement Association Of Colorado accumulated 319,099 shares or 0.07% of the stock. Rhumbline Advisers holds 0% or 65,930 shares in its portfolio. Sei Invests Company holds 73,988 shares or 0.01% of its portfolio. Stevens Capital Mgmt Limited Partnership has 14,885 shares for 0.02% of their US portfolio. Moreover, Spark Management Limited Com has 0.7% invested in Acorda Therapeutics Inc (NASDAQ:ACOR) for 292,400 shares. Bankshares Of Montreal Can holds 72,382 shares or 0% of its portfolio. Alps Advsrs accumulated 64,714 shares or 0.01% of the stock. Acadian Asset Management Lc accumulated 0.01% or 44,361 shares. Capstone Asset Mgmt Company holds 0.01% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 16,029 shares. Qs Investors Limited Co holds 0.02% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 110,290 shares. Point72 Asset Mngmt L P has 0.01% invested in the company for 75,600 shares. Capital Impact Advisors Limited Liability Company owns 9,000 shares or 0.11% of their US portfolio. Benjamin F Edwards Com reported 500 shares or 0% of all its holdings. Ls Advisors last reported 0% of its portfolio in the stock.

Insider Transactions: Since June 8, 2016, the stock had 0 insider buys, and 5 selling transactions for $168,893 net activity. Wasman Jane also sold $13,660 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) shares. Batycky Richard P. also sold $41,877 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) shares. Shares for $5,205 were sold by LAWRENCE DAVID on Friday, October 7. RAUSCHER STEVEN M sold $30,224 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) on Wednesday, June 8.

Acorda Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $961.51 million. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. It currently has negative earnings. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.

According to Zacks Investment Research, “Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company’s lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.”

ACOR Company Profile

Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. The Company’s research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. The Company’s Ampyra (dalfampridine) Extended Release Tablets, 10 milligrams, is used as a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, which are short-acting drugs for the management of spasticity, and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company’s pipeline of neurological therapies addresses a range of disorders, including MS, Parkinson’s disease, chronic post-stroke walking deficits (PSWD), epilepsy and migraine.

Another recent and important Acorda Therapeutics Inc (NASDAQ:ACOR) news was published by Marketwatch.com which published an article titled: “Acorda Therapeutics plummets as much as 13% on failed trial, discontinued drug …” on November 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>